ICVX Stock Overview
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Icosavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.31 |
| 52 Week High | US$16.11 |
| 52 Week Low | US$4.75 |
| Beta | 1.28 |
| 1 Month Change | -0.78% |
| 3 Month Change | 50.84% |
| 1 Year Change | 68.80% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.22% |
Recent News & Updates
Recent updates
We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth
Jul 04
Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?
Mar 10Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?
Oct 18Icosavax GAAP EPS of -$0.57
Aug 15Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones
Jul 28Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation
Jun 22Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation
Mar 24We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely
Oct 29Shareholder Returns
| ICVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | -2.5% | -3.2% |
| 1Y | 68.8% | -3.7% | 19.3% |
Return vs Industry: ICVX exceeded the US Biotechs industry which returned 4.8% over the past year.
Return vs Market: ICVX exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| ICVX volatility | |
|---|---|
| ICVX Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ICVX's share price has been volatile over the past 3 months.
Volatility Over Time: ICVX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 60 | Adam Simpson | icosavax.com |
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.
Icosavax, Inc. Fundamentals Summary
| ICVX fundamental statistics | |
|---|---|
| Market cap | US$777.79m |
| Earnings (TTM) | -US$96.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.0x
P/E RatioIs ICVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$70.04m |
| Gross Profit | -US$70.04m |
| Other Expenses | US$26.67m |
| Earnings | -US$96.71m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ICVX perform over the long term?
See historical performance and comparison